Apotex Pharmachem Inc.
USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2015–2017. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).
The verdict
According to USPTO PatentsView, Apotex ranks #38,814 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.
- #38,814
- of 49,997 US assignees by volume
- 26th percentile
- by Innovation Score (28.0/100)
- 22.3
- avg claims per patent
- -100%
- grant velocity, last 5 yrs
USPTO PatentsView assignee plate
Corpus R38814 · Foreign Corporation #38,814 · 6 grants
GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL
- GRANTS-MICRO 6 grants
- LOWER-Q #38,814/49,997
- PHOTO-FINISH Aon Global Risk…
- CPC-NARROW C07D · 5 areas
- INNOV-THIN 28.0/100
- CLAIMS-DENSE 22.3 claims/avg
- TYPE-FRNCORP Foreign Corp
- VEL-DROP -100% vel
- BOOK-FULL 10/10 fields
Nearest grant-volume peer: Aon Global Risk Research Limited (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
How Apotex’s 28.0 Innovation Score adds up
The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.
Innovation-score neighbourhood around Apotex
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
- Qualcomm Incorporated · highest
Qualcomm Incorporated · highest
85 score
- Apotex Pharmachem · this assignee 28
Apotex Pharmachem · this assignee
28 score
- 3D Lighting… · lowest 7
3D Lighting… · lowest
7 score
What this shows Apotex's Innovation Score is 28.0/100 (26th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Does more volume mean deeper claims for Apotex?
Each dot is one of Apotex’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Apotex’s own 22.3 claims/patent is ABOVE the 11.2 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.
Where Apotex's grants concentrate
Apotex Pharmachem Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2015 (3 grants) versus a trough of 1 in 2017. By volume, Apotex sits between Aon Global Risk Research Limited and Appcelerator, Inc..
Who files at Apotex's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Aon Global Risk R…
Aon Global Risk Research Limited
6 patents
- Apama Medical
Apama Medical, Inc.
6 patents
- Apex Neuro Holdin…
Apex Neuro Holdings, Inc.
6 patents
- Apexoem
ApexOEM, Inc.
6 patents
- Appformix
AppFormix Inc.
6 patents
- Appnexus
AppNexus Inc.
6 patents
- Appario Global So…
Appario Global Solutions (AGS) AG
6 patents
- Appcelerator
Appcelerator, Inc.
6 patents
- Apotex Pharmachem ◀
Apotex Pharmachem Inc.
6 patents
What this shows Apotex holds 6 patents at rank #38,914, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Apotex
By rank, the assignees closest to #38,914 in granted patent volume.
- Aon Global Risk Research Limited #38,910 · 6 patents
- Apama Medical, Inc. #38,911 · 6 patents
- Apex Neuro Holdings, Inc. #38,912 · 6 patents
- ApexOEM, Inc. #38,913 · 6 patents
- AppFormix Inc. #38,915 · 6 patents
- AppNexus Inc. #38,916 · 6 patents
- Appario Global Solutions (AGS) AG #38,917 · 6 patents
- Appcelerator, Inc. #38,918 · 6 patents
Leaders in C07D (Heterocyclic Compounds)
Other assignees with the most granted patents in Apotex's primary technology class.
Apotex's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
28 26th percentile higher than 26% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 50.0% |
| 2016 | 2 | 33.3% |
| 2017 | 1 | 16.7% |
Which technologies does Apotex Pharmachem Inc. patent most?
Top 5 of 5 technology areas
Data Source
USPTO PatentsView, US granted patents 2015–2025
What to do with this data
Apotex Pharmachem Inc.'s patent record in context - here's where to go next.
- Apotex Pharmachem Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
- Ranked #38,814 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
- Compare Apotex Pharmachem Inc. against Aon Global Risk Research Limited, an assignee filing at a similar volume. Compare portfolios
- Innovation Score of 28.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.